Sfoglia per AUTORE
ORSUCCI L
Collezione AOU Alessandria

  

Items : 12

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. in Blood advances / Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251.

2024
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara
ASL Biella

Bonomini L; Vitolo U; Cesaretti M; Esposito F; Pirosa MC; Pinotti G; Dore F; Pisani F; Zanni M; Ghiggi C; Liberati AM; Annibali O; Cabras MG; Celli M; Orsucci L; Tani M; Bruna R; Vanazzi A; Tucci A; Merli F; Balzarotti M; Gaidano G; Sassone M; Zucca E; Botto B; Stathis A; Ferreri AJM; Chiappella A; Conconi A; et alii...

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. in Haematologica / Haematologica. 2024 Aug 1;109(8):2564-2573. doi: 10.3324/haematol.2023.283918.

2024
AOU Alessandria
AOU Città della Salute di Torino

Bertoni F; Cavalli F; Landi F; Spina M; Re F; Pietrantuono G; Merli M; Houot R; Liberati AM; Haioun C; Devizzi L; Cartron G; Casasnovas RO; Angrilli F; Occhini U; Pulsoni A; Celli M; Califano C; Capochiani E; Cabras MG; Zanni M; Tilly H; Tessoulin B; Conconi A; Palombi F; Cavallo F; Morschhauser F; Gressin R; Marino D; et alii...

Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. in Leukemia / Leukemia. 2023 Feb;37(2):433-440. doi: 10.1038/s41375-022-01780-1. Epub 2023 Jan 18.

2023
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Pileri SA; Corradini P; Carniti C; Ciccone G; Tucci A; Boccomini C; Bermema A; Magagnoli M; Cavallo F; Leonardi F; Arcaini L; Patti C; Ballerini F; Musuraca G; Bruna R; Benedetti F; Volpetti S; Flenghi L; Celli M; Zilioli VR; Ilariucci F; Arcari A; Rossi FG; Zanni M; Ciancia R; Ghiggi C; Pinto A; Stefoni V; Usai SV; et alii...

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. in American journal of hematology / Am J Hematol. 2023 Dec;98(12):1856-1868. doi: 10.1002/ajh.27093. Epub 2023 Sep 29.

2023
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

De Paoli L; De Paolis MR; Delgado J; Dimou M; Donaldson D; Catherwood M; Doubek M; Efstathopoulou M; Eichhorst B; Elashwah S; Enrico A; Espinet B; Farina L; Ferrari A; Stamatopoulos K; Ghia P; Stavroyianni N; Trentin L; Cuneo A; Montserrat E; Vitale C; Coscia M; Rambaldi A; Iyengar S; Varettoni M; Yassin M; Pocali B; Vandenberghe E; van Kampen R; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. in Leukemia / Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.

2022
AOU Alessandria
AOU Città della Salute di Torino

Deckert M; Ponzoni M; Pennese E; Cabras G; Thurner L; Smith J; Rummel M; Hertenstein B; Schmoll HJ; Krause SW; Zanni M; Pisani F; Orsucci L; Tucci A; Panse J; Stilgenbauer S; Hess G; Keller U; Balzarotti M; Pukrop T; Gørløv JS; Linton KM; Johnson PW; Hemmaway C; Roth A; Krampera M; Ilariucci F; Fabbri A; Binder M; et alii...

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Penna G; Chiarenza A; Foà R; Derenzini E; Levato L; Orsucci L; Gottardi D; Gattei V; Gozzetti A; Gentile M; Sanna A; Olivieri J; Murru R; Stefoni V; Leone M; Baratè C; Marasca R; Malerba L; Ibatici A; Tisi MC; Chiurazzi F; Varettoni M; Del Poeta G; Marchetti M; Farina L; Giordano A; Foglietta M; Re F; De Paoli L; et alii...

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. in Blood / Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201.

2021
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Boccadoro M; Coscia M; Mauro FR; Foà R; Gaidano G; Tedeschi A; Scarfò L; Cuneo A; Orsucci L; Trentin L; De Paoli L; Reda G; Montalbano MC; Perutelli F; Gentile M; Boccellato E; Pennese E; Marchetti M; Laurenti L; Rivela P; Rigolin GM; Murru R; Vassallo F; Cassin R; Visentin A; Schiattone L; Zamprogna G; Porrazzo M; Griggio V; et alii...

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AOU Alessandria
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Piciocchi A; Cuneo A; Foà R; Rigolin GM; Fazi P; Neri A; Guarini A; Raponi S; Nanni M; De Propris MS; Della Starza I; Ibatici A; Murru R; Ruocco V; Del Giudice I; Varettoni M; Molinari A; Gentile M; Chiarenza A; Laurenti L; Gottardi D; Zinzani PL; Gozzetti A; Tani M; Musuraca G; Orsucci L; Re F; Di Renzo N; Liberati AM; et alii...

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. in Leukemia / Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.

2021
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Ghia P; Stamatopoulos K; Foà R; Cuneo A; Montserrat E; Rambaldi A; Coscia M; Yassin M; San Segundo LY; Wasik-Szczepanek E; Wróbel T; Visentin A; Vitale C; van Gelder M; van Kampen R; Varettoni M; Van Der Spek E; Trentin L; Tonino SH; Te Raa D; Tadmor T; Špa?ek M; Sportoletti P; Stavroyianni N; Stanca O; Shrestha A; Šimkovi? M; Saghumyan G; Qvist K; et alii...

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. in Leukemia / Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.

2020
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Ghia P; Cuneo A; Foà R; Montserrat E; Rambaldi A; Rossi G; Stamatopoulos K; Coscia M; Tam C; Zdrenghea M; Strugov V; Stavroyianni N; Stanca O; Shrestha A; Shah N; Rossi D; Papaioannou M; Ortiz Pareja M; Kalashnikova O; Enrico A; Hakobyan Y; Doubek M; Dimou M; Andres M; Nikitin E; Dos Santos G; Chiarenza A; Barna G; Pocali B; et alii...

Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. in Haematologica / Haematologica. 2018 Jun;103(6):1029-1037. doi: 10.3324/haematol.2017.186528. Epub 2018 Mar 22.

2018
AOU Alessandria
AOU Città della Salute di Torino

Galimberti S; Sanz RG; Cavallo F; Benevolo G; Orsucci L; Passera R; Omedè P; Zaccaria GM; Lia G; Muccio V; Mantoan B; Schirico ML; Guerrini F; Jiménez C; Ferrante M; Dogliotti I; Genuardi E; Drandi D; Boccadoro M; Ladetto M; Ferrero S;